Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial Read more about Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer Read more about Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach Read more about Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach
Perivascular Accumulation of Immunosuppressive Cells in the Stroma of Human Triple Negative Breast Carcinomas Read more about Perivascular Accumulation of Immunosuppressive Cells in the Stroma of Human Triple Negative Breast Carcinomas
Quantifying perivascular immune cells in the stroma of human triple negative breast tumors using deep learning spatial analytics Read more about Quantifying perivascular immune cells in the stroma of human triple negative breast tumors using deep learning spatial analytics
Evaluation of a tumor informed MRD assay with contrived breast cancer samples Read more about Evaluation of a tumor informed MRD assay with contrived breast cancer samples
Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence Read more about Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD) Read more about A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)
Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling Read more about Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling
Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer Using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort Read more about Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer Using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort